Clinical Trial Update: ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating ST-067 in combination with Teclistamab for relapsed or refractory multiple myeloma has been terminated. The update communica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ST-067
• Teclistamab (teclistamab)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: TERMINATED